Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
FOLLICULARDENDRITIC CELLSARCOMAR4洪逸平/VS顏厥全大夫
WHO classification of histiocyticand dendritic-cell neoplasms   Macrophage/histiocytic neoplasm     Histiocytic   sarcom...
Dendritic cell Sarcoma   A rare disease   Divided into interdigitating/follicular dendritic    cell sarcoma   IDCS is m...
Follicular Dendritic cellSarcoma   Nodal FDCS mostly affected cervical and    axillary lymph nodes   Extranodal FDCS mos...
Epidemiology   80 cases was documented until 2011 in    English literature Pancreat Dis Int,Vol 10,No 4 • August 15,2011 ...
Etiology   FDC express CD21 which is EBV receptor,    however the correlation is not well    documented   Hyaline-vascul...
Gross Pathology   Solid and tan, may be some hemorrhage or    necrosis
Histopathology   proliferation of spindle to ovoid cells that form    fascicles, storiform patterns, and whorls   Plump,...
CYTOLOGY by FNA
Immunohistochemistry (+): CD21, CD35, and CD23 (-): CD1a, lysozyme, myeloperoxidase, CD34,  CD3, CD79a, CD30, HMB-45, an...
Treatment   Complete surgical resection is the therapy of    choice   Adjuvant radiation or chemotherapy showed    indet...
Prognosis   As a low grade sarcoma with high local recurrence rate    but low metastasis risk       Overall recurrence: ...
Thanks for Yourattention!!
Upcoming SlideShare
Loading in …5
×

Follicular dendritic cell sarcoma

2,450 views

Published on

Published in: Health & Medicine, Technology
  • Be the first to comment

Follicular dendritic cell sarcoma

  1. 1. FOLLICULARDENDRITIC CELLSARCOMAR4洪逸平/VS顏厥全大夫
  2. 2. WHO classification of histiocyticand dendritic-cell neoplasms Macrophage/histiocytic neoplasm  Histiocytic sarcoma Dendritic-cell neoplasms  Langerhans cell histiocytosis  Langerhans cell sarcoma  Interdigitating dendritic cell sarcoma/tumor  Follicular dendritic cell sarcoma/tumor  Dendritic cell sarcoma, not otherwise specified
  3. 3. Dendritic cell Sarcoma A rare disease Divided into interdigitating/follicular dendritic cell sarcoma IDCS is more invasive Most of dendritic cell sarcomas (DCS) arise in lymph nodes, about 1/3 involve the extranodal sites
  4. 4. Follicular Dendritic cellSarcoma Nodal FDCS mostly affected cervical and axillary lymph nodes Extranodal FDCS mostly affected intra- abdominal organs and involves a wide variety of sites, including spleen, gastrointestinal tract, liver, soft tissue, skin, lung, and breast Metastatic disease is common in lymph nodes, lung, and liver
  5. 5. Epidemiology 80 cases was documented until 2011 in English literature Pancreat Dis Int,Vol 10,No 4 • August 15,2011 Hepatobiliary Onset age is various (9-82), mean age is about 50 Female: male: 1.2:1 Presentation: Painless, slow-growing mass Lab: anemia and elevated ALP in liver FDC Tumor is enhanced in PET
  6. 6. Etiology FDC express CD21 which is EBV receptor, however the correlation is not well documented Hyaline-vascular Castleman disease may be a predisposing factor to FDC p53 pathway may play a role Epidermal growth factor receptor(EGFR) expression has been investigated
  7. 7. Gross Pathology Solid and tan, may be some hemorrhage or necrosis
  8. 8. Histopathology proliferation of spindle to ovoid cells that form fascicles, storiform patterns, and whorls Plump, eosinophilic, fibrillary cytoplasm with indistinct cell border
  9. 9. CYTOLOGY by FNA
  10. 10. Immunohistochemistry (+): CD21, CD35, and CD23 (-): CD1a, lysozyme, myeloperoxidase, CD34, CD3, CD79a, CD30, HMB-45, and cytokeratins (+/-)Vimentin, desmoplakin, HLA-DR, CD68, and epithelial membrane antigen Mostly(-): S100 Others(+):Clusterin, fascin, podoplanin
  11. 11. Treatment Complete surgical resection is the therapy of choice Adjuvant radiation or chemotherapy showed indeterminate benefit The optimal combination treatment for FDC sarcoma has yet to be defined 2007;30:381–384 Onkologie Imatinib may be benefit
  12. 12. Prognosis As a low grade sarcoma with high local recurrence rate but low metastasis risk  Overall recurrence: 43%  Overall metastasis: 24%  Overall mortality: 17% Cancer. 1997;79:294–313.  2-year recurrence free survival: 62.3%  5-year recurrence free survival: 27.4% Virchows Arch. 2006;449(2):148–158 Poor prognostic factor:  intra-abdominal location,  size ≧ 6 cm,  mitotic count ≧ 5 per 10 high-power fields  coagulative necrosis  Significant nuclear pleomorphism  lack of adjuvant therapy
  13. 13. Thanks for Yourattention!!

×